[Withholding or withdrawing life-sustaining treatments in acute oncology situations: History and regulatory aspects in France].

La « Limitation et/ou arrêt des thérapeutiques » (LAT) en oncologie face à une situation aigüe : historique et aspects réglementaires en France.
Decisions to forgo life sustaining therapy Directives Anticipées End of life End of life decision making Limiting care Obstination déraisonnable Palliative care Therapeutic limitation Unreasonable Obstinacy Withdrawing Withholding advance directives collective procedure life-sustaining treatment «Limitation et/ou Arrêt des Thérapeutiques Actives»

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 02 07 2020
revised: 28 10 2020
accepted: 20 11 2020
pubmed: 9 3 2021
medline: 15 4 2021
entrez: 8 3 2021
Statut: ppublish

Résumé

The management of oncology patients, especially hospitalized patients, can lead to almost daily discussions regarding therapeutic limitations. Here, we review the history and propose a summary of the texts framing the notion of "withholding and withdrawing life-sustaining treatment" in oncology practice in France. This decision is regulated by the Claeys-Léonetti Law of February 2, 2016 recommending a collegial discussion and its documentation in the medical record. The decision to withhold or withdraw life-sustaining treatments is the subject of discussion between the patient, his physicians and his family and may take place at any time during his management. The work of intensive-care physicians provides many useful recommendations for acute oncology situations, however articles specific for oncology practice are scarce; this is a topic that oncologists must take up.

Identifiants

pubmed: 33678409
pii: S0007-4551(21)00046-1
doi: 10.1016/j.bulcan.2020.11.020
pii:
doi:

Types de publication

Historical Article Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

415-423

Informations de copyright

Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Capucine Aelbrecht-Meurisse (C)

Centre Oscar Lambret, département d'oncologie médicale, 3, rue Frédéric Combemale, 59000 Lille, France. Electronic address: c-meurisse@o-lambret.fr.

Thomas Ryckewaert (T)

Centre Oscar Lambret, département d'oncologie médicale, 3, rue Frédéric Combemale, 59000 Lille, France.

Diane Pannier (D)

Centre Oscar Lambret, département d'oncologie médicale, 3, rue Frédéric Combemale, 59000 Lille, France.

Vincent Gamblin (V)

Centre Oscar Lambret, département de soins palliatifs, 3, rue Frédéric Combemale, 59000 Lille, France.

Vincent Garcia (V)

Centre Oscar Lambret, département d'anesthésie-réanimation, 3, rue Frédéric Combemale, 59000 Lille, France.

Stéphane Aelbrecht (S)

EHPAD Les Myosotis, 160, rue Augustin Tirmont, 59283 Raimbeaucourt, France.

Nicolas Penel (N)

Centre Oscar Lambret, département d'oncologie médicale, 3, rue Frédéric Combemale, 59000 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH